Genitourinary Cancers
12 protocols meet the specified criteria.
-
A032103
MODERN: An Integrated Phase 2/3 and Phase 3 trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer -
A151804
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events -
A211901
Reaching Rural Cancer Survivors Who Smoke Using Test-Based Cessation Interventions -
EAY191
Molecular Analysis for Combination Therapy Choice (ComboMATCH) -
EAY191-N5
A Randomized Trial of Neratinib, A Pan-ErbB Inhibitor, Alone or in Combination with Palbociclib, A CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors - A ComboMATCH Treatment Trial -
GRAIL-MA-002
REACH Study: Real-world Evidence to Advance Multi-Cancer Early Detection Health Equity (REACH/Galleri-Medicare study) -
NRG-CC014
Radiation Therapy for High-Risk Asymptomatic Bone Metastases: A Pragmatic Multicenter Randomized Phase 3 Clinical Trial (PREEMPT) -
NRG-GU013
THE PHASE III HIGH FIVE TRIAL FIVE FRACTION RADIATION FOR HIGH-RISK PROSTATE CANCER -
NRG-GU014
Randomized Phase II Trial of Pembrolizumab and Radiation vs Radiation and Concurrent Chemotherapy for High-Grade T1 Bladder Cancer (PARRC) -
S1802
Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer -
S2312
A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with Metastatic Castrate Resistant Prostate Cancer (MCRPC), Stratified by Aggressive Variant Signature -
S2427
Single Arm Phase II Study of Bladder Preservation with Immunoradiotherapy After a Clinically Meaningful Response to Neoadjuvant Therapy in Patients with Muscle Invasive Bladder Cancer (BRIGHT)